Extended Data Table 4 Estimated mean changes in secondary and exploratory outcome measures from randomization (week 0) and from baseline (week −4) to week 24 in the intention-to-treat population including comparisons with early responders who were not randomized to a medication condition

From: Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial

  1. Data are estimated marginal means (±s.e.) for the intention-to-treat population (n = 131) derived from linear mixed models (two-sided α = 0.05). Early responders were not asked to provide a blood sample for laboratory data at week 0. BT, behavioral treatment; AOM, anti-obesity medication (phentermine = 15.0 mg d−1); BP, blood pressure; BPM, beats per min; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PHQ-9, Patient Health Questionnaire-9; QOL, quality of life; EI, eating inventory.
Back to article page